TABLE 1.

Circulating plasma HIV-1-specific IgG and IgA binding titers^a

Ig	Visit	Antibody titer (AUC)b
		Vaccine prime gp120, 92TH023 gp120c	Vaccine boost gp120		HIV-1 gp140		CD4bsd	V3 peptidese			C1 peptidee
			A244 gp120c	MN gp120c	1086 clade C gp140	Consensus gp140		V3 107 C	V3 B	V3 C	C1 BC	C1 AE
IgG	1	<100	<100	<100	<100	<100	<100	543	314	153.8	325	<100
	8	4,168	4,606	29,300	30,633	15,769	<100	440	6,347	3,806	1,978	2,192
IgA	1	<100	<100	<100	<100	<100	<100	194	<100	<100	<100	<100
	8	106	<100	1,635	566	185	<100	182	188	122	<100	<100

^aCirculating plasma HIV-1-specific antibody binding titers to HIV-1 envelope proteins and peptides were measured by binding antibody multiplex assay. Antibody titers, calculated as area under the curve (AUC), are shown for HIV-specific IgG and IgA at prevaccination visit 1 and 2 weeks after the last vaccination (visit 8). Data are representative of two independent experiments.

^bVisit 8 AUC values 3-fold greater than visit 1 values are in bold, and negative values of <100 are in italic.

^cEnv proteins contain the HIV-1 sequence without herpesvirus gD (75).

^dCD4bs specificity was tested by differential binding to YU2 old core/YU2 old core D368R and RSC3/RSC3 delta 371 (76).

^eSubtypes A, B, and C are noted.